On September 29, 2025, SciSparc Ltd. announced that N2OFF shareholders approved the merger with its majority-owned subsidiary MitoCareX, which focuses on drug discovery for resistant cancers like pancreatic and non-small cell lung cancer.
AI Assistant
SCISPARC LTD
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.